Employer GLP-1 Weight Loss Coverage

Key Takeaways

For 2026, this 4,000-life Ohio self-insured manufacturer should exclude weight-loss GLP-1s and reopen coverage only with BMI-gated prior authorization, lifestyle-tied renewals enforcing documented weight loss, plus a Wegovy-preferring net-cost PBM warranty, because according to HRP, Peterson-KFF, and Artificer Health open access drains roughly $5,980 per treated member yearly after limited offsets while persistence fails and weight returns ^[4][5][3].

• Follow peer majority and pause weight-loss coverage for 2026; according to Peterson-KFF employer tracking, EBRI modeling, and Ogletree employer review, most mid-size sponsors exclude weight-loss use while jumbo firms that cover tighten eligibility, leaving diabetes-only coverage as the holding pattern ^[5][8][7].
• Annual drug spend totals roughly $6,540 against about $560 in same-year medical savings in HRP cost-benefit analysis, leaving about $5,980 net loss per treated member with only 8.6% offset; in Mercer and InCareNow net-cost data, Wegovy averages near $6,830 yearly ($569 monthly) versus Zepbound near $8,500, equaling $5.69 versus $7.08 PMPM at 1% prevalence in this population ^[4][15][21].
• Nearly half discontinue by month 12, with one analysis pegging 12-month dropout at ~45%; discontinuers regain two-thirds of lost weight within 52 weeks off semaglutide with cardiometabolic markers drifting back in trial withdrawal summaries detailed by Pharmacy KnowHow, HRP analysis, and Fisher Phillips FAQs ^[20][4][2].
• Control spend only through enforced gates; under Artificer Health, DevotedDoc, and SmithRx protocols, plans require BMI 30+ alone or 27+ with comorbidity, time-limited initial approval, then renewal only after ≥5% loss for Wegovy with documented lifestyle effort, plus net-cost per-30-day guarantees, audit rights, and preferred-agent steering that moves PMPM more than list cuts ^[3][25][11].

[!WARNING] Evidence suggests open weight-loss coverage without gates locks in ~$6,540 yearly per user for ~$560 in savings while discontinuers forfeit two-thirds of loss, according to HRP analysis and Pharmacy KnowHow comparison ^[4][20].

Abstract

A self-insured Ohio manufacturer with 4,000 employees should end weight-loss GLP-1 coverage for 2026 and reinstate it only with strict eligibility, monitored continuation, and a net-price guarantee favoring Wegovy. Evidence suggests gated eligibility and net-price caps change that ^[3][11].

Peterson-KFF Health System Tracker and IFEBP analyses suggest weight-loss coverage stays rare among employers with 200 or more workers and clusters among sponsors with 5,000 or more lives, where use overshot forecasts, topped 10% of claims, and forced tightening ^[5][6]. Evidence from Ogletree and Mahoney Group surveys suggests covering employers largely intend to hold coverage while adding controls, while few diabetes-only or non-covering sponsors plan to add weight loss without better pricing ^[7][12]. Evidence from Mercer and Zepbound budget models suggests net cost near $6,830 annually for Wegovy ($569 monthly) versus about $8,500 for tirzepatide, or roughly $5.69 versus $7.08 per member per month at 1% prevalence in a 4,000-life group, doubling at 2% ^[18][21]. Evidence from Peterson-KFF comparisons suggests U.S. maintenance runs near $1,349 versus $328 in Germany and $296 in the Netherlands, and Novo Nordisk's $675 monthly list for 2027 reprices sticker toward net because Mercer expects rebates to shrink without lowering employer budgets ^[15][16]. One report suggests preferred Wegovy status cuts PMPM most ^[18].

Evidence from actuarial and pharmacy reviews suggests 12-month discontinuation averages about 45%, with estimates spanning 36% to over 50%, so the 14.9% mean loss on once-weekly semaglutide versus 2.4% on placebo at 68 weeks seldom survives in practice ^[20][24]. Evidence from real-world comparisons suggests tirzepatide averages about 15% loss versus about 8% for semaglutide at 12 months on treatment, a seven-point gap that determines who clears payer renewal cutoffs ^[20][19]. Withdrawal evidence suggests regain of two-thirds of lost weight within 52 weeks off semaglutide, and 14.0% regain after switch to placebo following 36 weeks of tirzepatide while continuers shed an additional 5.5% to week 88 ^[23][24]. Evidence suggests regain follows stopping quickly ^[23][24].

Evidence from HRP cost-benefit work and NIS Benefits modeling suggests average drug spend of $6,540 outweighs average medical savings of $560, leaving about $5,980 in net loss per treated member annually with only 8.6% offset in the same year ^[4][26]. Peterson-KFF and actuarial summaries suggest the shortfall stems partly from U.S. pricing at $1,023 monthly versus $444 in the Netherlands and $319 in Japan, while aggregate U.S. net spending on the class climbed from $13.7 billion in 2018 to $71.7 billion in 2023 ^[16][24]. Artificer and Devoted Health guides suggest controls that limit exposure: BMI 30 or higher alone or 27 or higher with comorbidity, structured lifestyle, time-limited approval, and renewal only after 5% loss for Wegovy and 4% for Saxenda with adherence checks, as UnitedHealthcare and Cigna apply them ^[3][25]. SmithRx and Mercer guidance suggests hardening those rules into PBM terms with net-cost guarantees per 30-day equivalent, full pass-through with audit and true-up, authorization-linked sharing, and quarterly tracking, because list discounts alone leave employer liability intact ^[1][11]. Published outcomes-guarantee results remain scarce ^[1][11][15]. The biggest gap involves multi-year total-cost data for a working-age manufacturing cohort.

Table of Contents

Key Takeaways Abstract

1. Introduction
2. Background
3. Findings 3.1 Peer Employer GLP-1 Coverage Decisions 2025-2026 3.2 Wegovy vs Zepbound Net Cost and PMPM Impact 3.3 Persistence Adherence and Weight Regain After Stopping 3.4 Offsetting Medical Savings and ROI Evidence 3.5 Utilization Management Strategies Controlling GLP-1 Spend 3.6 Outcomes-Based and PBM Contracting Strategies
4. Discussion
5. Conclusion References

1. Introduction

A 4,000-employee self-insured manufacturer in Ohio enters the 2026 plan year confronting a concrete coverage question: maintain coverage for Wegovy and Zepbound for weight loss, tighten access, or withdraw it ^[1]. Mercer identifies GLP-1 decisions for 2026 as live employer questions around cost, coverage design, and sustainability ^[1]. Employee demand collides with benefits budgets, a tension Healthee characterizes as the central employer challenge ^[9]. Through interviews with employers that cover GLP-1 agonists for weight loss, Peterson-KFF Health System Tracker traces how that pressure plays out in budgeting and employee relations ^[5]. Self-insured sponsors absorb pharmacy volatility directly and fund each paid claim from company assets ^[5]. The bill arrives monthly.

Peer practice sets the immediate context for renewal. One Mahoney Group survey report suggests coverage for GLP-1 weight-loss drugs has risen among employers ^[12]. Ogletree Deakins describes employers grappling with whether to add, keep, or limit that coverage as pharmacy trend climbs ^[7]. Tracking dollars, one International Foundation of Employee Benefit Plans report suggests GLP-1 drugs account for more than ten percent of annual claims in the plans it follows ^[6]. Evidence suggests demand and cost now interact, with Fisher Phillips mapping workplace questions tied to the rise of weight-loss drugs ^[2] and Vita Companies outlining coverage considerations for employers weighing weight-loss benefits ^[10]. Price announcements complicate the picture further. Mercer notes Novo Nordisk's GLP-1 list-price cut and flags variables employers should watch next ^[15]. One report suggests the Wegovy price cut could shift math for employer-sponsored insurance ^[18]. BioSpace tracks Novo's successive price reductions alongside emerging weight-loss data ^[19]. Prices move.

For a manufacturer, the decision reaches beyond trend. Fisher Phillips connects expanded GLP-1 use to workplace questions around accommodation, attendance policies, and productivity expectations ^[2]. One report suggests GLP-1 drugs link to a 17% drop in worker sick leave in a new economic study described by CBS News ^[17]. Evidence suggests workforce effects warrant attention alongside pharmacy spend, with Healthee tying coverage decisions to hiring and retention ^[9] and Carrum Health framing GLP-1 medications as an employer cost and care-management challenge ^[23]. Shift schedules, safety-sensitive roles, overtime coverage, and physical demands amplify any change in absenteeism or turnover on the plant floor. Actuaries track the same spillovers. The Society of Actuaries publication Actuary.org examines how GLP-1 drugs shape care, cost, and coverage for plan sponsors ^[24]. Compete for talent.

Gross cost obscures what sponsors actually pay. Peterson-KFF Health System Tracker compares U.S. prices for weight-loss drugs with peer-nation prices ^[16]. Evidence suggests net cost diverges sharply from list, with InCareNow outlining budgeting approaches for tirzepatide and Zepbound cost in 2026 ^[21] and NIS Benefits dissecting true employer cost after rebates, discounts, and fees ^[26]. A Washington Health Insurance Agency cost guide walks employer health plans through GLP-1 drug cost components and coverage mechanics ^[14]. Doctronic traces Zepbound cost without insurance as a reference point for cash-price exposure ^[22]. SmithRx outlines how employers can optimize benefits in the GLP-1 era through formulary, contracting, and management strategies ^[11]. Rebates muddy comparisons. Self-insured employers need per-member, per-treated-patient, and per-persistent-patient views to judge budget impact instead of relying on wholesale acquisition cost alone. Count net dollars.

Persistence and weight regain determine whether short-term pharmacy outlays translate into durable health gains. PharmacyKnowHow compares Wegovy and Zepbound using real-world clinical data ^[20]. Evidence suggests adherence patterns and discontinuation shape results, with Actuary.org reviewing how adherence, persistence, and coverage rules affect employer cost and care ^[24] and HRP framing GLP-1 coverage as a cost-benefit question that weighs drug spend against downstream medical effects ^[4]. Offsetting savings remain contested. EBRI simulates how GLP-1 coverage could affect employment-based plan premiums under varying uptake and pricing assumptions ^[8]. One report suggests reduced sick leave could signal productivity gains described by CBS News ^[17]. Employers ask whether fewer cardiovascular events, diabetes onsets, or orthopedic procedures follow sustained weight loss, and over what horizon. Time matters.

Outcomes-based arrangements attract attention but remain difficult to operationalize. Mercer fields employer questions on performance guarantees and outcomes-based contracting for GLP-1s in 2026 ^[1]. Evidence suggests plan sponsors pair formulary controls with lifestyle and persistence supports, with SmithRx describing benefit-optimization tactics for the GLP-1 era ^[11] and Vita Companies outlining employer action steps on coverage and care coordination ^[10]. Employers test step therapy, reauthorization tied to weight thresholds, and center-of-excellence models. Prove value first.

This report investigates five linked questions for the Ohio plan: what peer employers actually cover and why; what coverage costs net of rebates and fees on a per-member basis; how long members persist and what happens after stopping; whether medical or productivity offsets materialize; and which utilization-management and contracting tools contain cost without eroding value. Artificer Health details prior-authorization requirements by drug, indication, and payer for 2025-2026 ^[3]. DevotedDoc explains how GLP-1 prior authorization operates in practice ^[25]. AAOPM surveys which insurance plans cover weight-loss medication in 2026 ^[13]. The scope centers on weight-loss use of Wegovy and Zepbound in employer-sponsored, self-insured plans preparing for 2026 renewals. It excludes diabetes indications, Medicaid and Medicare rules, individual clinical guidance, and manufacturing-specific safety protocols except where benefits design touches attendance or fitness for duty. It also excludes speculative pipeline pricing. Background traces the rise of GLP-1s for weight loss and the plan-design options employers now weigh. Findings present peer coverage patterns, net-cost mechanics, persistence and regain evidence, offset studies, and management tools. Discussion interprets trade-offs for a mid-sized manufacturer. Conclusion distills decision inputs. Read ahead.

2. Background

Self-insured manufacturers in Ohio pay medical and pharmacy claims from company funds and hire third-party administrators and pharmacy benefit managers to negotiate discounts, build networks, and process bills, an arrangement that analyses from the Peterson-KFF Health System Tracker, Ogletree, and Healthee describe as preserving design control while concentrating budget risk on the sponsor ^[5][7][9]. Evidence from Fisher Phillips and Peterson-KFF employer interviews suggests manufacturing workforces carry elevated obesity-related risk linked to shift schedules, physical strain, and limited access to daytime care ^[2][5]. Federal ERISA rules let these self-insured plans set their own weight-loss drug rules outside state mandates, a flexibility Ogletree and Fisher Phillips flag for multi-state operators ^[7][2]. Stop-loss coverage caps individual catastrophic cases, yet evidence from Peterson-KFF and Ogletree employer accounts suggests it offers little protection against population-wide pharmacy spend ^[5][7]. Math compounds quickly.

GLP-1 receptor agonists mimic gut hormones that regulate appetite, slow gastric emptying, and amplify satiety signals after eating, a pharmacology that employer guides from Vita Companies, Carrum Health, and SmithRx summarize as shifting weight management from willpower narratives toward chronic-disease treatment ^[10][23][11]. Wegovy contains semaglutide and Zepbound contains tirzepatide, with tirzepatide acting on both GLP-1 and GIP receptors, a distinction real-world comparisons from PharmacyKnowHow and budgeting guides for tirzepatide document when contrasting mechanisms and dosing schedules ^[20][21]. Regulators cleared both products for chronic weight management alongside reduced-calorie diet and increased activity, while separate diabetes brands using the same molecules, Ozempic and Mounjaro, retain diabetes-only labels, a split coverage guides from AAOPM and the Washington Health Insurance Agency track for plan design ^[13][14]. Evidence suggests patients inject these weight-loss versions weekly at escalating maintenance doses rather than taking daily pills ^[20][22]. Persistence drives results.

Demand surged after diabetes patients lost substantial weight on GLP-1s and social and clinical attention pivoted to obesity treatment, a trajectory actuarial analysis from the American Academy of Actuaries and employer FAQs from Fisher Phillips trace through shortages, compounded alternatives, and expanded prescribing from 2022 through 2025 ^[24][2]. Evidence from the International Foundation of Employee Benefit Plans and Mercer suggests GLP-1s moved within two benefit cycles from niche diabetes therapy to more than ten percent of annual claims in some plans ^[6][1]. One report suggests manufacturing and other frontline employers felt the spike early because broad workforces adopted the drugs simultaneously across diabetes and weight-loss indications ^[6]. Plans scrambled to respond.

List prices in the United States dwarf those in peer nations, a gap the Peterson-KFF Health System Tracker quantifies by comparing American pharmacy prices for weight-loss GLP-1s with prices in the United Kingdom, France, Germany, and other high-income countries ^[16]. Evidence from Mercer analyses of Novo Nordisk list-price cuts and related commentary on the Wegovy price reduction suggests manufacturers have begun lowering headline prices and expanding cash-pay and direct-purchase channels in 2025 and 2026 ^[15][18]. Biospace coverage of Novo Nordisk’s successive cuts documents repeated downward moves tied to competitive pressure from Eli Lilly ^[19]. Net prices after rebates run lower. One report suggests cash-pay offers for Zepbound without insurance still leave monthly costs in the hundreds of dollars, limiting uptake without employer subsidy ^[22]. Rebates obscure true cost.

Peer employer coverage remains split between diabetes and weight-loss indications, a pattern Mercer 2026 guidance, Peterson-KFF employer interviews, and Ogletree explain as near-universal coverage for diabetes paired with selective, conditioned coverage for weight loss ^[1][5][7]. Evidence from the Mahoney Group survey and Mercer suggests the share of employers covering GLP-1s for weight loss rose through 2024 and 2025 but still trails diabetes coverage by a wide margin ^[12][1]. One report suggests jumbo employers lead that expansion while midsize self-insured sponsors weigh pilots and exclusions more cautiously ^[5]. The International Foundation of Employee Benefit Plans reports GLP-1s consuming over ten percent of annual claims in affected plans, a concentration that budget analyses from NIS Benefits and HRP cite when modeling 2026 exposure ^[6][26][4]. Finance teams notice.

Net cost per member reflects more than list price, encompassing rebates from manufacturers to pharmacy benefit managers, administrative fees, dispensing margins, and waste from early discontinuation, a stack that cost analyses from HRP, NIS Benefits, and SmithRx dissect for self-insured sponsors ^[4][26][11]. Evidence from HRP and NIS Benefits suggests headline rebates return a meaningful share of gross spend months after dispensing but vary by contract, volume, and whether the plan favors high-list, high-rebate products or low-list products ^[4][26]. The EBRI simulation-based premium model projects how broad weight-loss coverage without controls lifts employment-based premiums across risk pools, a framework EBRI, Mercer, and actuarial commentary use to translate per-prescription cost into per-member, per-month impact ^[8][1][24]. Budgeting guides for Zepbound urge sponsors to model take-up rates, titration waste, and concurrent lifestyle-program fees alongside drug spend ^[21]. Assumptions swing totals.

Utilization management now defines the baseline for any weight-loss benefit, with prior authorization serving as the gatekeeper, a process the Artificer Health prior-authorization guide and DevotedDoc explain as requiring documented body-mass index, comorbidities, prior weight-management attempts, and prescriber attestation by indication and payer ^[3][25]. Evidence from SmithRx and Ogletree employer accounts suggests leading plans add body-mass thresholds with comorbidity requirements, step therapy through lifestyle programs, quantity limits, and periodic reauthorization tied to documented weight loss and continued participation ^[11][7]. Reauthorization often checks adherence. One report suggests sponsors increasingly pair pharmacy controls with lifestyle-program enrollment, nutritional counseling, and exercise documentation rather than approving drugs alone ^[11]. Paperwork filters demand.

Persistence, the share of starters who refill continuously over 6 or 12 months, determines whether trial prescriptions convert into durable weight loss, a relationship employer care guides from Carrum Health and actuarial reviews emphasize when linking adherence support to outcomes ^[23][24]. Evidence from cost-benefit reviews and real-world effectiveness summaries suggests many patients stop within a year because of gastrointestinal side effects, cost sharing, shortages, or plateaued loss, which erodes average weight change across the treated population ^[4][20]. Head-to-head real-world data from PharmacyKnowHow and pricing commentary from Biospace indicate tirzepatide-based Zepbound produces larger average loss than semaglutide-based Wegovy in practice, though both require continued use to maintain effect ^[20][19]. Weight regain follows stopping. Evidence from reviews summarized for employers suggests most discontinuers regain a substantial share of lost weight within 12 months as appetite suppression fades ^[4][23]. Biology pulls back.

Offsetting medical savings remain difficult to isolate in employer time horizons, with cost-benefit analyses distinguishing short-cycle drug outlays from longer-cycle reductions in diabetes progression, cardiovascular events, orthopedic procedures, and absenteeism ^[4][26]. Evidence from the EBRI premium simulation and actuarial analysis suggests near-term pharmacy spend exceeds near-term medical savings for broad eligibility, pushing break-even years into the future absent targeting or price declines ^[8][24]. One report on a recent economic study of worker sick leave links GLP-1 use to a 17% drop in sick days, a productivity signal CBS News coverage highlights for employers weighing indirect returns ^[17]. Actuaries urge caution. Evidence from HRP and actuarial commentary suggests savings concentrate among members with high baseline risk and sustained adherence rather than spreading evenly across all starters ^[4][24]. Targeting shapes returns.

Outcomes-based and vendor strategies attempt to tie payment to persistence and weight change, with pharmacy benefit managers, point solutions, and centers-of-excellence vendors marketing bundled models, a landscape SmithRx, Carrum Health, and NIS Benefits map for sponsors evaluating 2026 options ^[11][23][26]. Evidence from SmithRx and Carrum Health guides suggests working approaches combine rigorous prior authorization, reauthorization at six and twelve months, side-effect management, diet and activity coaching, and data feeds that flag gaps in refills ^[11][23]. Budgeting tools for tirzepatide encourage sponsors to forecast scenarios by eligibility breadth, rebate pass-through, and cash-pay carve-outs before locking coverage language ^[21]. Contracts evolve slowly. One report suggests vendors increasingly offer rebate guarantees tied to adherence or weight-loss thresholds, though sponsors still negotiate audit rights and definitions of success ^[11]. Measurement stays messy.

3. Findings

3.1 Peer Employer GLP-1 Coverage Decisions 2025-2026

Peer employers have settled into a size-graded stalemate on weight-loss GLP-1s where jumbo sponsors cover at more than twice the rate of smaller large employers, as KFF data show ^[4][5]. KFF's 2025 Employer Health Benefits Survey puts coverage at 19% among firms with 200 or more workers and 43% among firms with 5,000 or more workers, a gap that directly determines how many workers face a formal exclusion ^[4][5]. Size predicts coverage in KFF data ^[4]. Peterson Center on Healthcare and KFF research repeats the same 19% and 43% split for the largest health plan in 2025, which forces mid-size sponsors to compete for talent without the same pharmacy benefit ^[7]. Artificer Health's read of KFF shows the inverse at 81% of firms with 200+ employees not covering GLP-1s for weight loss compared with 57% non-coverage among firms with 5,000+ employees, leaving most workers outside the benefit ^[3].

2025 looks flat rather than expansive because Mercer's 2024 baseline already locked in high coverage among the largest sponsors ^[1]. According to Mercer, 44% of employers with 500 or more employees covered weight-loss medications in 2024, and that coverage already consumed pharmacy budgets before the 2025 demand surge ^[1]. According to Mercer, 64% of employers with 20,000 or more employees covered weight-loss medications in 2024, which left the very largest sponsors with little room to add without restrictions ^[1]. According to Fisher Phillips, overall large-employer coverage of GLP-1s for weight loss showed little change from 2024 to 2025, so the year did not produce a broad take-up wave ^[2]. According to Mercer, the prior upward trend in weight-loss medication coverage may slow or even reverse under cost pressure, a forecast that disciplines 2026 planning ^[1]. Growth stalled per Fisher Phillips ^[2].

Coverage rates diverge cleanly when arrayed by employer size and peer cohort ^[5].

Jumbo employers drove the only real expansion, then hit a ceiling, as Fisher Phillips and Health System Tracker data show ^[2][5]. According to Fisher Phillips, about 43% of employers with at least 5,000 employees offered GLP-1 coverage for weight loss after an almost 54% increase over the prior year's results, which turned a niche benefit into a mainstream jumbo-employer question ^[2]. Very large employers remain split with less than half at 46% providing coverage according to Vita Companies, so even at the top the market never reached majority ^[10]. Coverage among firms with 5,000 or more workers rose from 28% in 2024 to 43% in 2025 according to the Health System Tracker analysis of Peterson-KFF data, a 15-point jump that explains why pharmacy spend spiked in that cohort ^[5]. Business Group on Health members cover at 67% for weight management according to Healthee, a higher rate that reflects a self-selected large-employer peer group rather than the full market ^[9]. Formulary presence now outpaces full weight-loss coverage, with approximately 45% of large employers including at least one anti-obesity medication on formulary, up from roughly 25% in 2023, according to AAOPM ^[13]. Momentum concentrated at the top per Fisher Phillips ^[2].

Keeping coverage in 2027 is the stated default among large peers that already cover, not an enthusiastic expansion, as Business Group on Health tracking reported by Healthee shows ^[9]. According to Healthee's account of Business Group on Health members covering GLP-1s for weight management, 72% planned to keep coverage in 2027, which locks in spend for another plan year ^[9]. About 10% of those covering members expected to drop coverage according to Healthee, so one in ten offers is explicitly at risk ^[9]. More employers are voluntarily covering weight-loss medications to recruit and retain talent according to Ogletree, a retention motive that makes dropping visible to workers ^[7]. Keeping is sticky per Healthee ^[9].

Restriction, not outright exit, absorbs most of the overshoot according to the International Foundation of Employee Benefit Plans and Mahoney Group ^[6][12]. Multiple sources report the overshoot for jumbo sponsors, with Fisher Phillips and the Health System Tracker each finding 59% of firms with 5,000 or more workers saying use was higher than expected ^[2][5]. The middle market felt it too, with 44% of firms with 1,000 to 4,999 workers saying use was higher than expected according to the Health System Tracker, which extends pressure below the jumbo tier ^[5]. Eligibility is the first lever, with 68% of covering employers using eligibility requirements as a cost-control option according to the International Foundation of Employee Benefit Plans ^[6]. Minimum BMI at 88% and obesity with one other chronic disease at 60% dominate eligibility designs according to the International Foundation of Employee Benefit Plans ^[6]. Tightening works per Health System Tracker ^[5]. Lifestyle conditions tripled to 34% in 2025 from 10% last year among covering firms according to the Health System Tracker, converting coverage into a conditional benefit ^[5]. Fisher Phillips puts the same lifestyle bar at 34% of employers offering weight-loss coverage requiring participants to meet with a dietician, case manager, or therapist or participate in a lifestyle program ^[2]. Wellness participation is now table stakes, with more than half of covering employers requiring lifestyle or wellness programs alongside prior authorization and step therapy to steer members to lower-cost steps first, according to HRP ^[4]. Mercer notes some employers are pairing weight-loss coverage with mandatory lifestyle programs to boost success rates, which adds a compliance hurdle to each fill ^[1]. Prior authorization is near-universal while formal step therapy remains selective, with 85% using utilization management and 18% using step therapy according to Mahoney Group ^[12]. According to the Health System Tracker, one large manufacturer illustrates the tightening sequence after grandfathering existing users by imposing a January 2024 requirement of type 2 diabetes for certain GLP-1s and a BMI of 35 or higher for weight-loss GLP-1s, directly raising the bar for new starts ^[5]. Higher cost sharing without formal dropping is spreading, with some plans placing GLP-1s in a higher formulary tier with higher out-of-pocket cost for the patient according to Ogletree ^[7]. Vendor control is next, with some employers exploring carve-outs that limit prescribing or dispensing to specific vendors according to Mercer ^[1].

Dropping or never starting remains the majority position outside the jumbo tier, executed through formal exclusions, as KFF and Healthee data show ^[3][9]. Formal exclusion is the mechanism, with 83% of employers who exclude weight-loss GLP-1s doing it through a formal carve-out from the medical or pharmacy plan according to Healthee ^[9]. Several firms that initially covered GLP-1 drugs for weight loss have since restricted coverage to only diabetes or specific indications or dropped weight-loss coverage entirely due to increases in use and costs, as the Health System Tracker employer focus groups found, turning early adoption into retrenchment ^[5]. Some have stopped covering these medications for weight loss, with a few even tightening up coverage for those with diabetes, according to Fisher Phillips employer discussions ^[2]. Cost pressure also pushes toward cost sharing, with some employers considering removing coverage or requiring members to share more of the cost according to Mercer ^[1]. Waiting dominates. A majority of non-covering employers said they were not likely to begin covering within the next 12 months and only 1% said they were very likely to do so according to Fisher Phillips, which freezes the non-covering pool ^[2]. Only 9% of non-covering employers are even considering adding coverage according to Healthee, so near-term conversion is thin ^[9]. Many non-covering employers are maintaining status quo while waiting for improved pricing or more competition according to Mercer ^[1]. Patience is strategic per Mercer ^[1].

Diabetes-only coverage is the consensus holding pattern that lets sponsors say yes without endorsing weight-loss use, as International Foundation of Employee Benefit Plans and Healthee trend data show ^[6][9]. Diabetes-only stood at 55% in 2025, down from 57% in 2024, while both diabetes and weight-loss coverage stood at 36%, up from 34%, according to the International Foundation of Employee Benefit Plans ^[6]. Diabetes-only climbed to 60% in 2026 from 55% in 2025 while both-indications coverage held at 36%, about the same as in 2025, according to Healthee ^[9]. The longer climb runs from 49% in October 2023 to 57% now for diabetes only and from 26% to 34% for both diabetes and weight loss according to Mahoney Group, which shows diabetes-only absorbing most growth ^[12]. The Employee Benefit Research Institute matches the split at 55% covering for diabetes and 36% for both diabetes and weight loss ^[8]. Comprehensive designs remain layered, with one 2025 survey summarized by the Washington Health Insurance Agency reporting 87% providing some GLP-1 coverage, including 35% for diabetes only, 23% for obesity along with cardiovascular risk, and 29% comprehensive, while 12% provided no coverage ^[14]. Broad-market take-up looks thinner, with about 23% of U.S. employers covering GLP-1 drugs for diabetes or weight loss in 2025 according to Ogletree's read of the Society for Human Resource Management survey ^[7]. Pipeline interest is narrow per International Foundation of Employee Benefit Plans ^[6]. Only 17% of diabetes-only sponsors are considering adding weight loss, down from 19% in 2024, according to the International Foundation of Employee Benefit Plans ^[6]. Nineteen percent of diabetes-only sponsors are considering extending to weight loss according to Mahoney Group ^[12]. Sponsors avoiding weight-loss coverage still fund access at the edges through pre-tax accounts, with HSAs or FSAs allowing pre-tax dollars for eligible prescriptions with possible employer contributions according to Fisher Phillips ^[2]. Fixed-budget reimbursement caps exposure, with health reimbursement accounts using pre-tax dollars and fixed annual maximums offering greater cost protection for employers avoiding broad coverage according to Ogletree ^[7]. An excepted benefit HRA could be up to $2,200 in 2026 and must stand alone and not be an integral part of the group health plan according to Ogletree ^[7]. Coverage stays narrow per Healthee ^[9].

Cost and use data from Fisher Phillips and the Health System Tracker explain why keep decisions come with strings attached ^[2][5]. Sixty-six percent of the largest employers said covering GLP-1 drugs for weight loss had a significant impact on prescription drug spending according to Fisher Phillips, a hit that makes renewal without controls untenable ^[2]. Impact scales with size, with 66% of firms with 5,000 or more workers and 43% of firms with 1,000 to 4,999 workers reporting a significant impact on prescription drug spending according to the Health System Tracker ^[5]. Sixty-four percent of large firms report moderate or significant impact on prescription drug spending according to SmithRx ^[11]. Claims concentration confirms the story, with 27% of employers saying GLP-1 costs exceeded 15% of annual claims and weight-loss use averaging 10.5% of claims in 2025, up from 8.9% in 2024 and 6.9% in 2023, according to the International Foundation of Employee Benefit Plans ^[6]. The climb continued to 11.4% of annual prescription drug claims by 2026 from 6.9% in 2023 according to Healthee, turning a specialty line into a top category ^[9]. One employer told the Health System Tracker that GLP-1s jumped from number 32 to number one in pharmacy spending within a year, compressing a multi-year trend into one renewal ^[5]. A 50% year-over-year increase in weight-loss GLP-1 spending forced one large manufacturer to increase copays for 2026 according to the Health System Tracker ^[5]. Managing overall GLP-1 costs is extremely or very important to 77% of large employers with 500+ employees according to Mercer's Survey on Health and Benefit Strategies for 2026, which elevates cost control above expansion ^[1]. Organizations keep exploring feasibility through cost-control mechanisms while balancing ongoing employee demand according to the International Foundation of Employee Benefit Plans ^[6]. Pressure sustains restrictions per Mercer ^[1].

3.2 Wegovy vs Zepbound Net Cost and PMPM Impact

Wegovy wins on employer net cost by roughly $1,670 per patient per year over Zepbound, with ICER pegging Wegovy at $6,830 annually or $569 monthly and Zepbound at around $8,500 annually, multiple sources report ^[18][22].

Do the math.

At those ICER nets, one continuously treated member adds about $0.14 PMPM for Wegovy and about $0.18 PMPM for Zepbound in a 4,000-life group, multiple sources report from ICER inputs ^[18][22]. A 1% treated prevalence, or 40 members on therapy, therefore translates to about $5.69 PMPM for Wegovy and about $7.08 PMPM for Zepbound, evidence suggests when ICER annual nets are annualized monthly ^[18][22]. Double treated prevalence to 2%, or 80 members, and the modeled burden doubles to about $11.38 PMPM for Wegovy and about $14.17 PMPM for Zepbound, multiple sources report from the same ICER inputs ^[18][22]. These medications can cost more than $1,000 per month before rebates according to the Washington Health Insurance Agency ^[14]. Rebates and discounts already reduce employers net cost below Wegovy new $675 list according to ICER using SSR Health net-price data ^[18].

Comparison of Wegovy and Zepbound list, net, and cash prices.

Novo Nordisk February 24, 2026 announcement of a $675 per month list for Wegovy, Ozempic and Rybelsus effective January 1, 2027 reprices the sticker toward net rather than cutting employer spend, multiple sources report from Mercer and Employer Coverage ^[15][18]. That $675 represents a 50% discount from Wegovy current cost and a 35% cut for diabetes drug Ozempic according to Biospace ^[19]. Ozempic and Wegovy share the same drug formulation in mostly the same doses, with the diabetes-labeled medication historically carrying the lower list price according to Employer Coverage ^[18]. List prices do not equal net prices paid because manufacturers provide insurer rebates and patient coupons according to the Health System Tracker brief, and Mercer describes the $675 move as another step narrowing that list-to-net gap, evidence suggests ^[16][15].

Ignore the sticker.

A one-month Wegovy maintenance supply lists at $1,349 in the United States versus $328 in Germany and $296 in the Netherlands according to the Health System Tracker brief ^[16]. That gap forces United States self-insured plans to absorb a fourfold markup before rebates according to the same Health System Tracker comparison ^[16]. One month of Ozempic lists at $936 in the United States, over five times Japan at $169 and about ten times Sweden, the United Kingdom, Australia and France according to the Health System Tracker brief ^[16]. One month of oral Rybelsus also lists at $936 in the United States, over four times the Netherlands price of $203 according to the Health System Tracker brief ^[16]. Self-insured budgets cannot be set from them.

Employers will pay the same or slightly more after the $675 cut when coverage and rebates adjust, with Mercer projecting no meaningful change in net costs after rebates and Employer Coverage warning of flat overall spending if Novo net revenue per dose holds, evidence suggests ^[15][18]. Mercer projects limited impact to aggregate net budgets and Novo itself says it does not expect the list reduction to impact net price, evidence suggests from Mercer and Employer Coverage accounts ^[15][18]. Novo is expected to offset the lower list price by reducing rebates according to Mercer ^[15].

Watch net, not list.

A lower list with unchanged coverage could paradoxically increase employer spending according to Employer Coverage ^[18]. Members paying coinsurance rather than flat copay may see lower pharmacy-counter costs while employers pay a slightly larger share of total costs for Wegovy, Ozempic and Rybelsus according to Mercer ^[15]. With a lower list price, the rebate tradeoff effects tied to restrictive management strategies may be smaller, which may change the cost-benefit balance for some plan sponsors according to Mercer ^[15]. Members may experience temporary delays at the pharmacy counter if some retail pharmacies scale back inventory ahead of the price change according to Mercer ^[15].

Wegovy incoming $675 list still runs higher than some direct-to-consumer offerings according to Mercer, while Health System Tracker employer perspectives peg Novo direct price at about $499 per month after an initial launch above $1,300, evidence suggests ^[15][5].

Follow the cash.

Novo self-pay option for Wegovy and Ozempic at $199 per month and its $150 price for initial doses of oral Wegovy widen that cash gap according to Biospace ^[19]. Novo and Lilly struck November White House deals to offer GLP-1 medicines through the Trump direct-to-consumer marketplace for about $350 per month according to Biospace ^[19]. About 27% of employers now direct employees toward direct-to-consumer pharmacy programs like NovoCare and LillyDirect where self-pay runs well below list according to Healthee ^[9]. Privately insured patients can use Wegovy coupons of $225 per 28-day supply for up to one year if their plan covers Wegovy, or $500 if it does not, according to the Health System Tracker brief ^[16]. Every cash fill steered off-plan trims measured PMPM while leaving cost with the member, which is why the 27% steer figure shapes net budget forecasts according to Healthee ^[9].

Zepbound cash ladder spans $299 to about $650 a month, less than half its list, with InCareNow and Doctronic pricing framing the endpoints, evidence suggests ^[21][22].

Map the leakage.

Zepbound manufacturer list of about $1,086.37 for a 28-day pen supply towers over LillyDirect vial entry at $299 per month for the 2.5 mg dose according to InCareNow ^[21]. Lilly cut direct prices to $299 for 2.5 mg from $349, to $399 for 5 mg from $499, and to $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg doses from $499 according to Biospace ^[19]. Those cuts map to cash vial pricing at $399 per month for 5 mg and $449 per month for 7.5 mg to 15 mg doses according to InCareNow ^[21].

Track leakage.

LillyDirect self-pay prefilled pens run approximately $550 to $650 per month depending on dose and pharmacy participation, or $6,600 to $7,800 annually, according to Doctronic ^[22]. That self-pay level represents roughly a 40% savings compared with standard retail according to Doctronic ^[22]. Single-dose vials cost less than pre-filled pens because pens charge for convenience while vials require syringe draw according to InCareNow ^[21].

Stay skeptical.

Annual vial treatment at $3,588 to $5,388 replaces more than $14,000 at list price according to InCareNow, which also cites full list above $14,000 per year without insurance or discounts ^[21]. Patients paying full retail without discounts face more than $12,700 annually while average retail without insurance exceeds $1,050 monthly according to Doctronic ^[22]. Doctronic HSA savings example cites a $1,086 monthly Zepbound prescription according to Doctronic ^[22]. Average retail cash runs about $1,291.34 for single-dose pens and about $599.85 for KwikPen or vials according to InCareNow ^[21]. GoodRx coupons lower Zepbound to around $980, roughly an 8-10% discount off average retail, according to Doctronic ^[22]. Eligible commercially insured patients pay as little as $25 for a 1- or 3-month supply with the manufacturer savings card according to InCareNow, but the Zepbound Savings Card requires commercial insurance covering Zepbound and excludes Medicare and Medicaid according to Doctronic, evidence suggests ^[21][22].

Formulary exclusion moves PMPM more than list cuts do, multiple sources report from Mercer and Artificer Health accounts of preferred-agent shifts ^[1][3].

Expect friction.

CVS announced it will exclude Zepbound starting July 1st while other major PBMs continue to offer both Zepbound and Wegovy according to Mercer ^[1]. CVS Caremark removed Zepbound from its standard commercial formulary effective July 1, 2025 naming Wegovy the preferred agent according to Artificer Health ^[3]. Prior authorization for Zepbound is common and delays the first fill by days or weeks according to InCareNow ^[21]. Anthem Blue Cross Blue Shield typically requires a trial of Saxenda or Contrave before approving Wegovy or Zepbound according to AAOPM ^[13].

Enforce stepwise.

Quantity limits cap weight-management fills at four pens per 28-day supply for Wegovy and Zepbound reflecting one weekly injection according to Artificer Health ^[3]. That four-pen cap directly caps per-patient monthly exposure in PMPM math according to the same Artificer Health limit ^[3]. Introducing a $90 copay reduced simulated premium increases across scenarios by 1-2 percentage points but could not fully neutralize expanded eligibility or perfect adherence effects according to EBRI ^[8]. The Food and Drug Administration has approved Wegovy and Zepbound to reduce excess weight and maintain reduction long term in adults with obesity or overweight with at least one weight-related condition when combined with diet and exercise according to Fisher Phillips ^[2]. Ozempic and Mounjaro were developed and approved for Type 2 diabetes while Wegovy and Zepbound were later approved for chronic weight management according to the Washington Health Insurance Agency ^[14]. Each control suppresses treated prevalence and therefore measured PMPM, which is why EBRI $90 copay still left residual premium pressure according to EBRI ^[8].

Twelve-month persistence below 30% for both Wegovy and Zepbound among initiating commercial patients cuts realized PMPM far below perfect-adherence models according to PharmacyKnowHow citing Prime Therapeutics commercial pharmacy claims and Trilliant Health national claims datasets ^[20].

Model quits.

Durable efficacy with either agent requires unbroken long-term maintenance rather than a finite treatment course because rebound magnitude is comparable across agents according to PharmacyKnowHow ^[20]. Continuous therapy locks in PMPM for years. The SELECT trial in 17,604 adults showed semaglutide 2.4 mg reduced major adverse cardiovascular events by approximately 20%, with events 6.5% versus 8.0% placebo and hazard ratio 0.80 with 95% confidence interval 0.72-0.90, leading to March 2024 FDA approval of Wegovy for cardiovascular risk reduction that created a Medicare Part D coverage pathway according to Artificer Health ^[3]. Wegovy received a supplemental cardiovascular indication in March 2024 permitting Medicare Part D sponsors to cover Wegovy under secondary cardiovascular prevention benefits, bypassing the statutory weight-loss exclusion, according to PharmacyKnowHow ^[20]. Compounded tirzepatide is not FDA-approved like brand Zepbound and quality can vary between pharmacies according to InCareNow ^[21]. The worker sick-leave paper published this month by the National Bureau of Economic Research lists Duke University professor Jonathan Zhang among co-authors according to CBS News ^[17]. Productivity offsets do not cut pharmacy PMPM.

3.3 Persistence Adherence and Weight Regain After Stopping

Twelve-month persistence fails for nearly half of GLP-1 starters, and that failure erases most of the drugs' population benefit. Claims analyses consistently show 36% to over 50% discontinuing within 12 months, with Oxford researchers estimating about 45% globally stop by one year. That breaks the model. Trial averages assume continuous exposure, while real-world cohorts fracture early. High headline weight-loss figures from SURMOUNT-1 or STEP-1 presume near-complete adherence under protocol conditions and do not reflect real-world persistence, according to PharmacyKnowHow ^[20]. Payers still pay launch prices for truncated courses, then pay again for regain.

Headline efficacy of 15%-20% body-weight loss versus 3-4% with placebo holds only under protocol adherence, and multiple sources report the same boundary condition. Multiple sources report clinical-trial losses between 15%-20% compared with placebo at 3-4%, according to Vita Companies ^[10], while once-weekly semaglutide 2.4 mg produced mean loss of 14.9% at week 68 versus 2.4% with placebo in STEP-1, according to PharmacyKnowHow summarizing Wilding et al. ^[20]. Those numbers force chronic exposure. Stop the exposure and the arithmetic collapses, because the placebo-adjusted gap was bought with 68 weeks of continuous dosing, titration visits, and lifestyle co-intervention.

Tirzepatide beats semaglutide by about seven points at 12 months when patients actually stay on drug, which sharpens the persistence penalty for the weaker agent. In a 12-month on-treatment real-world cohort, tirzepatide achieved mean change of approximately −15% versus −8% for semaglutide, a difference of roughly 7.0 percentage points favoring tirzepatide with 95% CI −7.9% to −6.5%, according to PharmacyKnowHow ^[20]. Evidence indicates tirzepatide also carried higher likelihood of reaching 5% and 15% thresholds in that cohort ^[20]. Small gap? No. Seven points decides who clears payer renewal cutoffs and who repays full cost for no durable result.

Even next-generation combinations do not escape the exposure requirement, they raise the stakes for staying on therapy. In head-to-head Phase REDEFINE 4, CagriSema — a fixed-dose combination of 2.4 mg semaglutide and 2.4 mg cagrilintide — elicited 23% weight loss over 84 weeks compared with 25.5% for Zepbound, according to BioSpace ^[19]. That result matters. Higher ceilings mean larger absolute regain when injections stop, and 84-week courses demand even longer persistence than current 68-week paradigms.

Stopping semaglutide erases two-thirds of lost weight within a year off drug, and cardiometabolic gains go with it. Investigators followed STEP-1 participants for 52 weeks after withdrawing semaglutide 2.4 mg and lifestyle intervention, and patients regained two-thirds of prior weight loss by week 120, according to PharmacyKnowHow ^[20]. Blood pressure, glycated hemoglobin, and lipid improvements reverted toward pre-treatment baseline over that same off-drug year ^[20]. Short version: the disease returns. Weight is not banked, it is rented with weekly dosing, and the lease expires fast once injections cease.

Stopping tirzepatide reverses the trajectory even faster in randomized withdrawal, with continuers still losing while switchers regain. By week 88, patients continuing tirzepatide maintained reduction and achieved an additional 5.5% loss, while patients switched to placebo after 36 weeks regained 14.0% of body weight, according to PharmacyKnowHow summarizing SURMOUNT-4 ^[20]. The 14.0% regain is not noise. It exceeds an entire year of semaglutide real-world effectiveness, wiping out the average on-treatment outcome in months, and the withdrawal regain penalty lands hardest on high responders who have the most to lose.

Comparison of post-discontinuation regain across randomized and observational summaries shows the same direction with different magnitudes.

Weight regain after stopping is the rule, not the exception. Once medication stops, weight regain is common with many people gaining back up to three-quarters of what they lost, according to Carrum Health ^[23]. Studies of GLP-1 discontinuation indicate patients regain weight they lost while taking GLP-1s, according to the Employee Benefit Research Institute ^[8]. Vita Companies summarizes the pattern as much, if not all, of the weight regained after discontinuation ^[10]. Stopping Zepbound often leads to weight regain, according to Doctronic ^[22]. The consistency across randomized withdrawal and observational follow-up leaves no durable off-drug effect to underwrite short courses.

Early discontinuation is driven by gut intolerance colliding with coverage friction during titration. Primary attrition drivers include gastrointestinal intolerance during dose escalation, prior authorization hurdles, step-therapy mandates, and formulary exclusions, according to PharmacyKnowHow ^[20]. Nausea peaks exactly when paperwork peaks. Patients titrate through vomiting and diarrhea while pharmacies demand re-authorizations, documented diet failures, and step-througholder generics, and either intolerance or denial ends the course before week 12 effectiveness can compound.

Payers convert persistence into a renewal test that many truncated courses cannot pass. Renewal requires ≥5% body-weight loss from baseline for Wegovy and ≥4% for Saxenda plus continued documented lifestyle modification measured from baseline weight recorded at prescription initiation, according to Artificer Health summarizing UnitedHealthcare and Cigna rules ^[3]. Miss the renewal weight test and coverage stops. Coverage stopping then guarantees regain, which guarantees re-eligibility debates later at a higher baseline weight and with diminished motivation.

Chronic-use expectations make the persistence problem explicit: 12 to 24 months minimum, often indefinitely. Weight-management medications like Zepbound typically require ongoing use to maintain results, with most patients planning at least 12 to 24 months and many continuing indefinitely, according to Doctronic ^[22]. That horizon controls budgets. A therapy priced as a short intervention but dosed as a lifelong therapy forces employers and plans to fund continuous refills or fund regain, with no middle path where a brief course delivers lasting remission.

Demand itself is persistence-sensitive, falling when patients learn results require indefinite payment. About half of U.S. adults would be interested in prescription weight-loss drugs, but interest drops if the drug is not covered by insurance or after hearing patients might gain weight back after stopping use, according to KFF polling summarized by KFF and the Peterson Center ^[16]. Coverage loss kills initiation. Regain knowledge kills persistence motivation before the first pen, because patients correctly infer that a drug requiring permanent use without permanent coverage is a bridge to nowhere.

3.4 Offsetting Medical Savings and ROI Evidence

Employers lose roughly $5,980 per GLP-1-treated member per year after medical offsets, according to HRP Insights ^[4]. Annual medical savings average roughly $560, while average annual GLP-1 drug cost reaches $6,540, according to the same HRP Insights cost-benefit analysis ^[4]. That $6,540 pharmacy outlay clears in the same plan year. The math is brutal. The $560 offset covers only about 8.6% of drug spend, which forces sponsors to fund more than eleven dollars in drug cost for every one dollar of medical savings recaptured that year, according to HRP Insights ^[4]. Short-term return on investment stays negative for most employers under that arithmetic, according to HRP Insights ^[4]. Pharmacy reimbursement is immediate and certain. Offsets are delayed, partial, and shared with other stakeholders, which leaves the employer holding the deficit at renewal.

Even complete elimination of obesity-related excess medical spend would not pay for GLP-1 therapy in the coverage year. Adult obesity is associated with $1,861 in average extra annual medical costs per person, rising to $3,097 for severe obesity, according to the National Library of Medicine report summarized by HRP Insights ^[4]. Those $1,861 and $3,097 figures bound the theoretically avoidable medical spend in one year. Evidence suggests a $6,540 drug bill exceeds the average obesity surcharge by $4,679 and still exceeds the severe-obesity surcharge by $3,443 ^[4]. Multiple sources report that gap prevents pharmacy-led total-cost reduction even under optimistic offset assumptions ^[4]. Realized savings look smaller still. The $560 in observed savings equals only about 30% of the $1,861 average excess and about 18% of the $3,097 severe-obesity excess, which limits what plans capture early, according to HRP Insights ^[4]. The resulting net pharmacy loss persists unless price falls or the time horizon lengthens. Stop expecting one-year offsets to close it.

The short-term cost tsunami easily dwarfs any savings, according to the Actuary.org analysis of GLP-1 care, cost, and coverage ^[24]. That tsunami hits pharmacy trend immediately across expanding eligible populations, while medical savings arrive slowly and unevenly across subgroups. Attribution is hard. Attributing improvements to a specific therapy is inherently difficult outside controlled clinical trials, according to the same Actuary.org analysis ^[24]. When members start therapy while also changing diet, activity, primary-care engagement, and concomitant cardiometabolic prescriptions, before-and-after claims comparisons cannot isolate the injection effect, according to Actuary.org ^[24]. Plans observe lower admissions or improved labs. They cannot prove causation. That evidentiary gap keeps finance teams from treating disease-specific wins as bankable for premiums or budgets. Evidence indicates reported improvements remain directional until trial-grade attribution exists ^[24].

There are no brand-name medicines that lower total medical cost over a population, according to the Employer Coverage analysis ^[18]. That historical regularity disciplines GLP-1 expectations. Brand drugs routinely improve health while raising total spend, which justifies coverage on clinical value rather than medical-cost offset. Multiple sources report short-term GLP-1 costs overwhelm the $560 in realized savings ^[4][24]. The pattern is familiar. The population cost rule holds because drug spend is universal among treated patients while avoided events are rare, delayed, and distributed across medical, disability, and government budgets. Employers that underwrite GLP-1s as a cost-saving intervention misprice the product. They purchase health gain at net new spend.

U.S. plan sponsors pay more than twice the Dutch price and more than three times the Japanese price for the same GLP-1 month. A month of Mounjaro (tirzepatide) lists at $1,023 in the U.S. compared to $444 in the Netherlands and $319 in Japan, according to Health System Tracker ^[16]. That $579 monthly premium over the Netherlands and $704 premium over Japan compounds directly into employer loss. Prices explain much. The $6,540 average annual U.S. drug cost already produces negative short-term return on investment, according to HRP Insights ^[4], and the $1,023 monthly list price implies even larger gross exposure before rebates, according to Health System Tracker ^[16]. U.S. ROI arithmetic is therefore geography-specific. It cannot be imported from systems paying $444 or $319 per month.

Monthly Mounjaro list-price comparison across the United States and two peer nations.

Aggregate U.S. exposure exploded before broad weight-loss coverage matured. Net U.S. spending on the drug class increased from $13.7 billion in 2018 to $71.7 billion in 2023, an increase of more than 500%, according to UnitedHealthcare ^[14]. That $58 billion increment reshapes trend. Scale matters. A $5,980 per-patient shortfall becomes a budget event when multiplied across diabetes, emerging obesity, and cardiovascular eligibility pools, according to UnitedHealthcare trend data combined with HRP Insights per-member arithmetic ^[14][4]. Evidence suggests aggregate budget impact now dominates employer discussions even where per-patient clinical value is accepted ^[14][4]. Pharmacy-and-therapeutics committees approve on efficacy. Finance committees live with $71.7 billion in national net spend.

Productivity gains exist, but they do not accrue to the payer funding the prescription. In Denmark, fewer short-term illnesses saved employers money, while fewer long-term absences saved the government money, according to CBS News reporting on the worker sick-leave study ^[17]. That split fractures the business case. Employers capture avoided short spells. Governments capture avoided disability. The distinction is decisive. An employer that pays $6,540 per treated worker per year, according to HRP Insights ^[4], cannot monetize government savings from fewer long-term absences reported in Denmark, according to CBS News ^[17]. Societal value rises. Payer return does not. Self-insured sponsors evaluating absence data must therefore separate employer-paid sick days from taxpayer-funded disability before crediting productivity offsets to the drug budget.

A drug can be high value per quality-adjusted life year and still destroy a one-year pharmacy budget. Health economists generally consider drugs costing less than $100,000 or $150,000 per QALY to be high value, according to the Employer Coverage analysis of cost-effectiveness benchmarks ^[18]. That $100,000 or $150,000 per QALY threshold measures lifetime health gain per dollar, not cash-flow neutrality. The confusion is costly. Cost-effectiveness justifies higher spend for longer, healthier life. Return on investment demands lower total spend within the contract period. A therapy that clears the $150,000 per QALY bar easily still requires $6,540 upfront against $560 in near-term medical savings, according to HRP Insights ^[4], which fails any one-year payback test while potentially passing a lifetime value test summarized by Employer Coverage ^[18]. Benefits committees should judge accordingly. Buy health, not savings.

Total cost of care does not fall in the near term when GLP-1s are covered broadly at U.S. prices. HRP Insights quantifies the $560 versus $6,540 shortfall ^[4], Actuary.org describes the short-term cost tsunami dwarfing savings and the attribution problem outside controlled trials ^[24], UnitedHealthcare quantifies the $13.7 billion to $71.7 billion surge ^[14], and the Employer Coverage population-cost finding establishes that no brand-name medicine lowers total medical cost over a population ^[18]. The conclusion is accounting. Pharmacy spend is immediate, universal among users, and priced at $1,023 per month in list terms in the United States ^[16], while the maximum avoidable obesity excess is $1,861 on average and $3,097 for severe obesity ^[4]. Targeting changes the slope. Concentrating coverage on severe obesity raises the $3,097 ceiling relative to the $1,861 average, according to the National Library of Medicine report ^[4], but even the higher ceiling sits $3,443 below $6,540 in drug cost ^[4]. Time changes the slope. Longer horizons allow cumulative comorbidity and productivity effects, including the Denmark short-term versus long-term absence split ^[17], to accumulate against repeated annual drug outlays. Price changes the slope fastest. Movement from $1,023 toward $444 or $319 per month rewrites every employer model ^[16].

3.5 Utilization Management Strategies Controlling GLP-1 Spend

Prior authorization decides who actually gets a GLP-1. Seventy-eight percent of employers covering GLP-1 drugs use utilization management as a cost-control mechanism, according to IFEBP ^[6]. Ninety-six percent of that utilization-management subset require prior authorization, according to IFEBP ^[6]. Gatekeeping is routine. Virtually every insurer covering weight-loss medication requires documented medical necessity, BMI criteria, failed lifestyle intervention, and often a lower-cost trial first, according to AAOPM ^[13]. Insurers increasingly use prior authorization with criteria more restrictive than FDA labeling, according to the University of Pennsylvania Leonard Davis Institute of Health Economics as summarized by DevotedDoc ^[25]. Many plans now pair prior authorization with step therapy requiring lower-cost or lifestyle-based options first, according to NIS Benefits ^[26]. That stack makes approval the exception. Small paperwork gaps trigger denial.

The BMI gate is standardized at BMI ≥30 kg/m² alone or BMI ≥27 kg/m² with comorbidity, and that standardization is what makes it enforceable. UnitedHealthcare 2026 policy P 1114-20 and Cigna policy IP0206 both state that verbatim threshold, according to Artificer Health ^[3]. Plans using BMI-plus-comorbidity criteria often require BMI exceeding 27 plus documented obesity-related comorbidity, according to Vita Companies ^[10]. Aetna commercial group plans require BMI 30+ or 27+ with comorbidity plus prior authorization, according to AAOPM ^[13]. Documentation of BMI or related conditions may be required for coverage, according to InCareNow ^[21]. Standard prior authorization requires current BMI from a clinical measurement within the past 30 days, according to AAOPM ^[13]. That 30-day freshness rule prevents stale numbers from sustaining eligibility. Employers seeking tighter control raise the floor to BMI 35 or higher to restrict availability and cost exposure to severe obesity, according to Vita Companies ^[10]. Higher cutoffs shrink the eligible pool immediately.

The comorbidity list is long enough to matter for contracting and narrow enough to deny. Cigna IP0206 explicitly lists hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, PCOS, and coronary artery disease as qualifying for the BMI ≥27 pathway, according to Artificer Health ^[3]. Typical BMI-plus-comorbidity examples include high blood pressure, dyslipidemia, heart disease, sleep apnea, and cardiovascular disease, according to Vita Companies ^[10]. Requiring participation in lifestyle programs, limiting to higher-risk populations, and applying BMI-based criteria are named coverage-management strategies, according to Mercer ^[15]. Some employers require prior authorization, a BMI threshold, or participation in a weight-management program before coverage, according to Ogletree ^[7]. Clinical prior authorization requiring BMI threshold plus weight-related comorbidity with a consistent and understandable review is recommended practice, according to the Washington Health Insurance Agency guide ^[14]. Precision helps audits. Vague comorbidity language invites appeals.

UnitedHealthcare and Cigna enforce the same BMI rule with different clocks. Short initial windows force early proof of response. Miss the window and therapy stops.

Comparison of UnitedHealthcare and Cigna weight-management controls.

The diabetes-versus-weight-management brand split lets plans deny a prescription that is chemically familiar. The same active ingredient may be sold under one brand for diabetes and another for chronic weight management, with coverage for one not guaranteeing coverage for the other, according to DevotedDoc ^[25]. Some health plans exclude medications prescribed specifically for weight management even when patients meet medical criteria because the drug is not on formulary for that purpose, according to DevotedDoc ^[25]. Ozempic and Mounjaro were not FDA-approved for weight loss or weight management as of publication despite sometimes being prescribed off-label for that use, according to Fisher Phillips ^[2]. That regulatory distinction arms pharmacy benefit managers. Strong evidence-based prior authorization should ensure medical necessity and confirm patients tried front-line therapies like low-cost generics and lifestyle programs when clinically appropriate, according to SmithRx ^[11]. A risk-based clinical review evaluating the full profile including other conditions and past medications matches the right patient to the most appropriate medication, according to SmithRx ^[11]. Wrong-brand prescribing wastes appeals.

Step therapy forces cheap generics first in diabetes and documents failure first in weight management. Most commercial payers require metformin at maximally tolerated dose with documented inadequate response, intolerance, or contraindication before approving a GLP-1 for type 2 diabetes, according to Artificer Health ^[3]. Many plans also require one additional antidiabetic agent, commonly an SGLT2 inhibitor, sulfonylurea, or DPP-4 inhibitor, according to Artificer Health ^[3]. Some plans require a standard GLP-1 before tirzepatide, according to Artificer Health ^[3]. That sequence delays the expensive agent. Some plans require patients to try another covered treatment before approving the requested GLP-1, according to DevotedDoc ^[25]. Providers may need to document which medications or programs were tried, how long they were used, and why they were ineffective or inappropriate, according to DevotedDoc ^[25]. Step therapy asking members to try a lower-cost option before a higher-cost GLP-1 with reasonable exceptions when clinically inappropriate is recommended design, according to the Washington Health Insurance Agency guide ^[14]. Exceptions preserve safety. Poor documentation still blocks approval.

Lifestyle pairing is the only utilization control that extends persistence instead of just blocking starts. Most payers require documented enrollment in a structured weight-management program prior to or concurrent with anti-obesity medication therapy, with Cigna requiring minimum 3 months documented lifestyle modification while UnitedHealthcare requires lifestyle modification as adjunct with counseling but no minimum month count, according to Artificer Health ^[3]. Essentially all pre-authorization programs require at least concurrent commitment to lifestyle modifications, and many require 3-6 months of diet and exercise modification before access, according to Vita Companies ^[10]. Weight-management coverage may be tied to a concurrent lifestyle or clinical program including nutrition support, behavioral coaching, regular follow-up, or prior consideration of other approaches, according to the Washington Health Insurance Agency guide ^[14]. Virtually every insurer covering weight-loss medication requires failed lifestyle intervention among its criteria, according to AAOPM ^[13]. Lifestyle proof is mandatory. Three months of coaching costs less than three months of drug.

Reauthorization converts a one-time approval into chronic-disease management. Initial authorization runs 5 months for Wegovy and 6 months for Zepbound under UnitedHealthcare versus 8 months for both under Cigna, with 4 months for Saxenda under UnitedHealthcare and 12-month renewal for all three, according to Artificer Health ^[3]. Those time-limited initial approvals force weight, tolerability, and adherence checks before continuation ^[3]. Providers should track expiration dates and resubmit renewals 30 days before expiration, according to AAOPM ^[13]. Thirty days prevents gaps. Plans should distinguish clinical eligibility, ongoing follow-up, and appropriate continuation to contain budget impact from high per-member-per-month cost and growing utilization, according to the Washington Health Insurance Agency guide ^[14]. Obesity is a chronic condition that may require ongoing management so coverage decisions affect pharmacy spending over multiple plan years, according to the Washington Health Insurance Agency guide ^[14]. Multi-year liability starts at reauthorization.

Cardiovascular risk reduction creates a side door with easier entry and longer tenure. The Wegovy cardiovascular pathway requires only BMI ≥27 with prior myocardial infarction, stroke, or peripheral artery disease and has no behavioral counseling prerequisite, 12 months initial authorization, and anti-obesity-medication exclusion riders do not apply, according to Artificer Health ^[3]. Twelve months doubles the shortest weight-management window. That design reflects outcomes data. The SELECT trial evaluating semaglutide 2.4 mg weekly in 17,604 patients with established cardiovascular disease and overweight or obesity without diabetes produced a 20% relative risk reduction for major adverse cardiovascular events with hazard ratio 0.80, 95% CI 0.72-0.90, p<0.001, according to Pharmacy Know How ^[20]. Twenty percent fewer events justifies payer tolerance for longer approvals. Plans still verify the qualifying event.

Tapering exposes the missing evidence payers use to justify time limits. It remains unclear whether patients must take these drugs for life or in combination with other procedures and therapies, according to the Health System Tracker ^[16]. Uncertainty favors limits. Requiring participation in a clinical weight-management or lifestyle program helps employees stay on track, with coaching and nutrition support linked to longer persistence and retaining results if tapering off, according to Healthee ^[9]. Coaching extends value after the last injection. Obesity already costs the U.S. health system an estimated $173 billion annually with $1,800-$3,000 in additional medical costs per adult each year, according to NIS Benefits ^[26]. That baseline makes indefinite therapy fiscally fraught. Monthly out-of-pocket costs exceeding $1,000 for many branded weight-loss medications make insurance the access determinant, according to AAOPM ^[13]. One thousand dollars monthly ends self-pay persistence quickly.

Rebates punish tightness and reward breadth, which reverses the obvious savings logic. Plans imposing stricter BMI thresholds or more restrictive prior authorization may limit utilization but receive less generous rebates, increasing net cost per prescription, while broader access may increase total utilization while lowering net unit cost, according to Actuary.org ^[24]. Tight gates raise unit cost. Preliminary Milliman real-world data found increased GLP-1 adherence may lower medical costs for certain chronic conditions but does not fully offset the high drug cost, according to Actuary.org ^[24]. Offsets help but do not pay the bill. Models show premiums rising several percentage points more under perfect adherence than under real-world use because short-term drug costs outpace savings, according to NIS Benefits ^[26]. Perfect adherence maximizes pharmacy spend first. Obesity contributes to other high-cost conditions including musculoskeletal pain, diabetes, and cardiovascular disease, implying cuts to weight-loss coverage could increase other medical costs, according to Carrum Health ^[23]. Narrow pharmacy savings can inflate medical spend. Coordinated metabolic care combining nutrition-first weight loss, diabetes reversal, and responsible GLP-1 prescribing with value-based specialty pathways claims to lower total cost of care for employers and members, according to Carrum Health and Virta Health ^[23]. Coordination is pitched as the escape from unit-cost arithmetic.

The next pipeline molecule already shapes formulary steering. Lilly's triple-G competitor retatrutide showed around 17.5% weight loss in a Phase 2 study, according to BioSpace reporting BMO ^[19]. Seventeen-point-five percent resets efficacy expectations and intensifies prior-authorization scrutiny. BMO analysts view Novo's incretin products as clinically disadvantaged versus Lilly's tirzepatide, according to BioSpace ^[19]. Perceived disadvantage invites preferential tiering. Plans will use step therapy and brand-specific authorization to steer toward the perceived winner.

3.6 Outcomes-Based and PBM Contracting Strategies

Employers that chase headline direct-to-consumer prices for GLP-1s without auditing their pharmacy benefit manager net position will frequently overpay. Mercer reports that what employers pay is usually far below the list price thanks to negotiated rebates that PBMs pass back to them, and that their net-of-rebate price may be comparable to or even better than the direct-to-consumer price despite DTC prices being lower than list, according to Mercer ^[1]. That finding forces a sequencing discipline for 2026 contracting. Plan sponsors must demand a timely reconciliation of gross spend, rebate invoicing, and pass-back percentage before approving any alternative channel. Check net first. A team that skips that step risks dismantling a rebate stream that already beats retail cash pricing and then paying twice to rebuild adherence support outside the benefit.

Rebate leverage remains a negotiable asset rather than a fixed discount schedule. Private insurers and employers in the U.S. may be able to negotiate lower prices with drug manufacturers or get larger rebates, according to the Health System Tracker ^[16]. The practical consequence is that sponsors should treat every renewal as a repricing event. Contracts that lock in a stated discount off list without a rebate pass-through definition, an audit right, and a market-check clause surrender that leverage. Sponsors with credible volume, tight formularies, or willingness to impose clinical rules can press for improved base rebates, supplemental indication-specific rebates for weight management, and administrative fee transparency. Keep pressure on. Evidence from Mercer on net-of-rebate parity with DTC pricing ^[1] combined with Health System Tracker evidence on negotiability ^[16] suggests sponsors have room to improve net unit cost without changing clinical policy, and multiple sources report that retained PBM channels can still compete with cash alternatives when actively managed.

List-price cuts do not reset the underlying net-price trend. BMO expects net pricing declines to continue to occur over time but says list price adjustments are unlikely to significantly impact the rate of these net price declines, according to BMO reporting carried by BioSpace ^[19]. That distinction matters for guarantee design. A guarantee anchored to a percentage discount off list can look improved after a manufacturer lowers list while the plan's actual per-prescription net cost barely moves. Sponsors should therefore anchor financial guarantees to net cost per paid claim, net cost per 30-day equivalent, and aggregate rebate dollars per utilizer rather than to list-based discounts. Hold to net. The contracting implication is to require PBMs to true up shortfalls on net-cost guarantees in cash, to define whether supply fees, clinical program fees, and retained rebate dollars count toward the guarantee, and to prohibit reclassification of manufacturer payments to evade the calculation. Evidence indicates list adjustments alone will not accelerate savings ^[19], so sponsors that fail to rewrite guarantee definitions will book paper savings while pharmacy trend persists.

Prior authorization remains the cheapest proxy for an outcomes contract when true weight-loss warranties are unavailable. Some employer plans require prior authorization in which a clinician must document that the member meets plan criteria before the prescription is approved, according to the Washington Health Insurance Agency ^[14]. That documentation requirement creates the enforceable gate that outcomes language needs. Sponsors can define covered use by plan criteria, require initial clinical documentation, and condition continuation on documented persistence, tolerance, and follow-up visits. The data generated at authorization and reauthorization becomes the outcomes registry. Deny and document. Without that gate, any promise to pay only for appropriate use is unenforceable, and continuation therapy flows to members who never met entry standards or who discontinued lifestyle support. Evidence indicates a clinician attestation model can support both cost control and later outcomes measurement ^[14], which gives sponsors leverage to demand PBM reporting on approval rates, denial reasons, time to decision, and continuation rates by cohort.

Flat copays waste an opportunity to price adherence and persistence. Employers can customize member cost-sharing and copays to encourage appropriate use and shared financial responsibility, and SmithRx advises partnering with a PBM that can customize member cost-sharing based on the client's goals ^[11]. That customization is where outcomes-based design actually lives in commercial pharmacy contracts today. Sponsors can tier cost-sharing by authorization status, require higher cost-sharing for continuation without documented follow-up, reduce cost-sharing for members enrolled in nutrition, exercise, or behavioral programs, and reset cost-sharing if therapy is interrupted and restarted without clinical review. Share the cost. The mechanism aligns financial responsibility with expected benefit without excluding eligible members outright. Evidence indicates customizable cost-sharing can be operationalized through the PBM when the client defines the goals in advance ^[11], which means sponsors must write those goals into the benefit exhibit rather than leaving cost-share design to standard PBM templates.

Carve-outs that subsidize cash purchases fracture accumulation logic and measurement. Some vendors now allow employers to subsidize employees' purchases at DTC prices, although those payments generally cannot be applied to deductibles or out-of-pocket maximums, according to Employer Coverage ^[18]. That single accumulation rule changes the economics for members and for plan accounting. A member who pays several hundred dollars per month through a subsidized DTC route makes no progress toward deductible satisfaction or out-of-pocket protection, then faces full cost-sharing if hospitalization or specialty care occurs later in the year. The employer meanwhile pays twice, once for the subsidy and once for the unmanaged medical risk that continuous coverage might have reduced. Track accumulation. Evidence indicates the DTC subsidy path operates outside the benefit accumulator ^[18], so sponsors considering it must model total member financial burden, not just per-fill drug cost, and must require vendors to supply fill, persistence, and discontinuation feeds to preserve any outcomes oversight.

Comparison of PBM contracting routes for GLP-1 weight-loss spend.

Ohio operations cannot rely on public coverage to absorb commercial GLP-1 demand for obesity. AAOPM places Ohio in the limited non-GLP-1-only category that covers Contrave, Qsymia, or orlistat but excludes GLP-1s for the obesity indication, alongside Illinois, Pennsylvania, and Michigan, according to AAOPM ^[13]. That benefit baseline shapes strategy for employers with Ohio manufacturing, distribution, or headquarters footprints. Commercial plans in Ohio must carry the full weight of any obesity GLP-1 coverage decision because Medicaid does not create a coverage bridge for low-wage, part-time, or waiting-period workers who might otherwise qualify. The formulary contrast is explicit. Contrave, Qsymia, or orlistat remain the only anti-obesity options in that public benchmark, which forces Ohio sponsors to decide whether commercial coverage mirrors that conservative list or deliberately diverges with strict authorization and cost-sharing. Plan locally. Evidence indicates Ohio's public exclusion of GLP-1s for obesity persists ^[13], so multi-site employers cannot assume a uniform national access environment and should set Ohio-specific communications, provider education, and prior-authorization capacity rather than importing coverage assumptions from states with broader Medicaid GLP-1 coverage.

The next generation of contracts should price persistence and net cost, not list discounts and rebate percentages alone. With a lower list price the rebate tradeoffs tied to high-list, high-rebate strategies may be smaller, which may change the cost-benefit balance for some plan sponsors deciding between retaining rebates and pursuing DTC or transparent net-price models. Sponsors can operationalize that shift by combining the tools above into a single exhibit. Require full pass-back of negotiated rebates with quarterly reconciliation, consistent with Mercer's description of rebates PBMs pass back ^[1] and Health System Tracker evidence that larger rebates remain negotiable ^[16]. Define net-cost-per-treated-member guarantees that survive list-price adjustments, consistent with BMO expectations that net declines continue while list moves matter little to the rate ^[19]. Condition payment on prior-authorization documentation that the member meets plan criteria ^[14] and on customized cost-sharing tied to client goals for appropriate use and shared responsibility ^[11]. Isolate any DTC subsidy as a defined pilot with its own budget, with explicit acknowledgment that those payments generally cannot be applied to deductibles or out-of-pocket maximums ^[18]. Benchmark Ohio plan design against the state's limited non-GLP-1-only Medicaid coverage of Contrave, Qsymia, or orlistat with exclusion of GLP-1s for obesity ^[13]. Measure quarterly. That structure converts an outcomes aspiration into auditable pharmacy language without waiting for manufacturers to offer formal weight-loss warranties.

4. Discussion

For a 4,000-life self-funded Ohio manufacturer, annual arithmetic overwhelms clinical enthusiasm. One employer cost-benefit analysis from HRP estimates yearly drug outlay near $6,540 against $560 in same-year medical offsets, leaving roughly $5,980 unrecovered for each treated enrollee and offsetting only 8.6% of pharmacy spend ^[4]. The deficit described in Section 3.4 anchors the decision. Peer practice sharpens the point described in Section 3.1: evidence suggests most smaller large employers hold exclusion and diabetes-only coverage while jumbo sponsors absorb the surge, with Peterson-KFF employer interviews detailing use exceeding expectations and Mercer 2026 guidance ranking GLP-1 cost control as a top priority ^[5][1]. The International Foundation of Employee Benefit Plans puts GLP-1s above ten percent of annual claims ^[6]. Arithmetic dominates. Prevalence turns a per-person shortfall into plan-level pressure no in-year wellness dividend closes.

Drug choice tempers but never erases that shortfall. Evidence suggests budget guides place Wegovy net near $6,830 yearly, $569 monthly, and Zepbound near $8,500, a gap near $1,670 per continuous patient that lifts a 40-member cohort to about $5.69 per member per month versus $7.08 ^[21][22]. The load modeled in Section 3.2 makes the trade explicit. One head-to-head real-world comparison from PharmacyKnowHow reports roughly 15% loss on tirzepatide at 12 months versus about 8% on semaglutide, a seven-point edge ^[20]. The implication tracked in Section 3.3 matters for renewals. Should the plan pay the premium for extra pounds? Efficacy costs extra. One prior-authorization guide notes renewals hinge on at least 5% loss for Wegovy with documented lifestyle effort, so nonresponders lose coverage anyway while responders require indefinite refills ^[3]. Steering toward the lower-net option trims losses without fixing persistence.

Persistence breaks the promise. Evidence suggests about 45% of starters stop before month 12, with estimates spanning 36% to over half, so trial curves assuming continuous titration with lifestyle support never materialize for nearly half the cohort ^[23][24]. The falloff detailed in Section 3.3 undercuts durable response. Evidence suggests quitters regain two-thirds of prior loss within 52 weeks off semaglutide with blood pressure, glycemic and lipid gains sliding toward baseline, while a tirzepatide switch-to-placebo arm regained 14.0% after 36 weeks as continuers shed another 5.5% to week 88 ^[20][23]. The fade explained in Section 3.4 erases offsets with weight. Can delayed savings still catch up? One analysis finds offsets arrive partial, late and split across medical, disability and government budgets, with concurrent diet, activity and engagement changes confounding attribution outside controlled trials ^[4]. The plan funds ongoing refills or funds regain.

Gates beat stickers. Evidence suggests standard prior authorization bars access below BMI 30 alone or 27 with comorbidity, insists on current measurement, structured lifestyle, step through lower-cost agents and separates diabetes brands from weight-management brands ^[3][25]. The controls detailed in Section 3.5 decide who treats. One guide from Artificer Health catalogs UnitedHealthcare and Cigna sharing BMI cutoffs yet diverging on lifestyle duration, with time-limited initials then longer renewals tied to tolerance, adherence and response, plus a separate longer cardiovascular pathway without counseling prerequisite ^[3]. One EBRI simulation suggests a $90 copay trims premium pressure 1 to 2 points without neutralizing expanded eligibility or perfect adherence ^[8]. The repricing reframed in Section 3.2 disappoints. Evidence suggests Novo's announced $675 monthly list for Wegovy, Ozempic and Rybelsus effective January 2027 reprices sticker toward net while rebates shrink, leaving employer net largely unchanged and potentially lifting member coinsurance share ^[15][18]. Controls move spending. Headlines do not.

Cash distracts. Mercer and SmithRx playbooks urge employers to reconcile gross spend, rebate invoices and pass-back first, because net-of-rebate often lands far below list and matches or beats cash, with rebate terms negotiable at renewal ^[11][15]. The reconciliation outlined in Section 3.6 precedes any direct-to-consumer pilot. Evidence suggests cash menus list $199 monthly self-pay for Wegovy and Ozempic and $299 to about $650 across Zepbound vials and pens ^[19][22]. The alternatives priced in Section 3.2 invite bypass. Do cash routes relieve the plan? Evidence suggests they generally raise combined outlay because outside-benefit purchases skip deductibles and out-of-pocket maxima, fragment oversight and evade enforceable gates unless data flow back, a hazard where Ohio public coverage excludes GLP-1s for obesity ^[11][13]. Mercer and SmithRx contracting guidance outweighs cash-price marketing for budget planning because the former audits net per claim, per 30-day equivalent or per utilizer with true-up while the latter quotes sticker without rebates or persistence ^[11][15][26]. One true-cost review notes list declines alone rarely alter net trajectory ^[26].

The talent argument tempts. Keep open coverage, advocates urge, because one survey reports about half of U.S. adults voice interest, exclusion feels punitive in a tight hiring market, lifetime value clears $100,000 to $150,000 per quality-adjusted life year, Wegovy's March 2024 cardiovascular indication promises fewer major events, and one economic study links GLP-1s to a 17% fall in short-term sick leave ^[2][4][24]. The demand pressure acknowledged in Section 3.1 collided with budgets, while the lifetime-value framing acknowledged in Section 3.4 differs from contract-period neutrality ^[5][4]. Why sacrifice recruitment, morale and long-run health for one-year optics? The rebuttal turns on who captures what when. One analysis estimates even erasing average excess obesity costs of $1,861, $3,097 for severe obesity, leaves drug spend ahead, with observed savings capturing only about 30% and 18% respectively ^[4]. A Peterson-KFF price comparison shows U.S. list of $1,023 versus $444 in the Netherlands and $319 in Japan ^[16]. One actuarial review tracks aggregate net class spend vaulting from $13.7 billion in 2018 to $71.7 billion in 2023, with short-term illness relief helping the script payer while long-term absence savings accrue elsewhere ^[24][17]. Concede the point that survives: attendance and perceived generosity likely improve while scripts continue. That morale gain matters. It cannot finance itself.

Uncertainty remains. Evidence suggests twelve-month discontinuation spans 36% to over half across definitions, and continuous-treatment models assume durability refill data contradict ^[23][24]. The spread carried in Section 3.3 clouds forecasting. Evidence suggests regain summaries range from two-thirds within a year off drug to much to three-quarters after stopping, with varying follow-up, dose and support ^[20][23]. The attribution limits shown in Section 3.4 compound the fog. One analysis cannot disentangle drug effect from diet, activity, engagement and other scripts, net-price opacity keeps plan-specific rebates hidden behind modeled $6,540 versus $6,830 benchmarks, and no Ohio 4,000-life manufacturing cohort supplies local persistence or offset data ^[4][21]. One trial summary reports 23% loss with CagriSema over 84 weeks versus 25.5% for Zepbound, assuming extended exposure that magnifies absolute regain if stopped ^[20]. Outcomes-based contracting lacks published performance; audit rights promise discipline without proof. For budget planning, HRP modeling and EBRI simulation outweigh vendor cash guides because they expose net and premium effects. Treat premium and regain figures as directional, not guaranteed.

Exit by default. For 2026, the 4,000-person Ohio self-funded operation should suspend weight-management drug reimbursement unless clinical, lifestyle and purchasing protections lock together. The gate supported in Section 3.5 means BMI-anchored prior authorization with measured documentation and brand separation ^[3][25]. The contract supported in Section 3.6 means audited net-unit protection with true-up ^[11][26]. Concretely, admit only BMI 30-plus or 27-plus with comorbidity, authorize briefly, then continue solely with verified program participation plus percentage loss meeting label thresholds, while the pharmacy contract guarantees net per 30-day unit, favors the lower-net weekly semaglutide product, passes rebates fully and tracks every fill in one registry. Two variables dominate all else: unrecovered spend for each treated enrollee and quit-regain dynamics. Either alone sinks open access; together they foreclose it. Impose all three restraints or decline coverage.

5. Conclusion

For 2026, this 4,000-life Ohio plan should withdraw reimbursement for weight-management GLP-1s unless procurement secures gated eligibility by BMI, continuation only after measured loss plus lifestyle engagement, and a net-unit-cost warranty steering to Wegovy.

Peer practice already leans out ^[5][7]. Evidence from Peterson-KFF Health System Tracker and Ogletree suggests most sponsors with 200 or more workers still bar weight-loss use, while coverage clusters among jumbo employers with 5,000-plus lives who now tighten eligibility after spend overshot forecasts ^[5][7]. One Mercer briefing suggests the 2026 default among coverers holds maintenance only with tighter controls, not broader access ^[1]. One IFEBP tally suggests GLP-1s exceed ten percent of annual claims in exposed plans ^[6]. Go narrow.

Open coverage bleeds cash ^[4]. One HRP analysis suggests yearly drug outlay hits $6,540 against $560 in same-year medical savings, leaving roughly $5,980 unrecouped per treated member and offsetting only 8.6% of pharmacy spend ^[4]. On near-term budget neutrality, evidence cuts decisively against open coverage ^[4]. One Peterson-KFF price comparison suggests U.S. list tops $1,000 monthly, with Wegovy maintenance listed at $1,349 domestically versus $328 in Germany and $296 in the Netherlands ^[16]. Evidence from Mercer and employer-coverage analysis suggests the announced $675 monthly list for 2027 reprices sticker toward net without cutting employer net, because rebates will shrink to match ^[15][18]. Evidence from SmithRx and employer-coverage work suggests exclusion, preferred-agent shifts, prior authorization and four-pen-per-28-day limits move budgets more than list cuts ^[11][18]. Enforce gates.

Persistence breaks the clinical promise ^[10][24]. Evidence from employer guides and actuarial review suggests 36% to more than 50% quit within 12 months, with about 45% stopping by one year, so trial losses assuming continuous dosing rarely transfer ^[10][24]. One PharmacyKnowHow comparison suggests tirzepatide averages about 15% loss versus about 8% for semaglutide at 12 months, a seven-point gap that determines who clears renewal cutoffs ^[20]. One Carrum Health guide suggests quitters regain two-thirds of prior loss within 52 weeks off semaglutide, with blood pressure and lipid gains fading toward baseline ^[23]. Evidence from real-world comparison and actuarial review suggests tirzepatide continuers shed another 5.5% to week 88 while switchers to placebo regained 14% ^[20][24]. Evidence from authorization guides suggests renewal typically requires at least 5% loss for Wegovy plus documented lifestyle work ^[3][25]. No refills, no result.

Controls decide spend ^[3][25]. Evidence from Artificer Health and DevotedDoc suggests routine gates include BMI 30-plus alone or 27-plus with comorbidity, current measurement, structured lifestyle, step therapy, and brand separation so diabetes approval never unlocks weight-loss pens ^[3][25]. One Artificer guide suggests UnitedHealthcare and Cigna share BMI rules but differ on lifestyle duration and time-boxed starts renewed only on response and tolerance ^[3]. One SmithRx guide suggests reconciling gross, rebate invoice and pass-back first, then guaranteeing net per 30-day equivalent with audit and true-up, not list discounts ^[11]. One Mercer note suggests list cuts alone will not bend net trajectory ^[15]. Tight wins. Whether tapering or maintenance dosing holds loss after 24 months remains unclear amid pipeline claims near 23% loss, and that uncertainty counsels renting outcomes, not buying indefinite refills.

The case for staying open still bites. One CBS-reported study suggests GLP-1s cut worker sick leave 17% ^[17]. Evidence from cost-benefit and actuarial work suggests brand medicines can improve health while lifting total spend because avoided events arrive rare and late, yet drugs under $150,000 per quality-adjusted life year still carry high lifetime value ^[4][24]. Broad access also helps hiring. Keep that signal. Default flips only when talent or equity risk outweighs pharmacy math: then fund diabetes and CVD indications separately, push cash-pay pilots outside the benefit with data capture, and revisit when net prices fall. One coverage guide suggests Ohio public programs still limit obesity coverage to non-GLP-1 options, so no public floor rescues a loose commercial design ^[13]. Gate or exit.

At 1% uptake through December 2026, a BMI-gated Wegovy-preferred program will hold realized drug spend near $5.69 per member per month while an open Zepbound-leaning program will top $7.08 and still lose nearly half its starters by month 12 ^[8][20].

References

^[1] GLP-1 considerations for 2026: Your questions answered! — https://www.mercer.com/en-us/insights/us-health-news/glp-1-considerations-for-2026-your-questions-answered/ · general ^[2] Employer FAQs on the Rise of GLP-1 Drugs for Weight Loss and the Workplace Impact — https://www.fisherphillips.com/en/insights/insights/employer-faqs-on-the-rise-of-glp-1-drugs-for-weight-loss-and-the-workplace-impact · general ^[3] GLP-1 Prior Authorization Guide: Requirements by Drug, Indication, and Payer (2025–2026) — https://www.artificerhealth.com/blog/glp1-prior-authorization-guide/ · general ^[4] GLP-1 Coverage Cost-benefit Analysis — https://hrp.net/hrp-insights/glp-1-coverage-cost-benefit-analysis/ · general ^[5] Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss - Peterson-KFF Health System Tracker — https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/ · general ^[6] GLP-1 Drugs Responsible for Over Ten Percent of Annual Claims — https://www.ifebp.org/detail-pages/news/2025/05/22/glp-1-drugs-responsible-for-over-ten-percent-of-annual-claims · general ^[7] Employers Grapple With GLP-1 Coverage for Weight Loss — https://ogletree.com/insights-resources/blog-posts/employers-grapple-with-glp-1-coverage-for-weight-loss/ · general ^[8] GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums: A Simulation-Based Analysis — https://www.ebri.org/content/glp-1-coverage-and-its-impact-on-employment-based-health-plan-premiums--a-simulation-based-analysis · general ^[9] The GLP-1 employer coverage dilemma: Balancing employee demand and benefits budgets — https://healthee.com/blog/glp-1-employer-coverage/ · general ^[10] GLP-1 Drugs for Weight Loss: What Employers Need to Know — https://vitacompanies.com/blog/glp1-drugs-for-weight-loss-what-employers-need-to-know · general ^[11] How Employers Can Optimize Benefits in the Era of GLP-1s | SmithRx — https://smithrx.com/blog/optimizing-benefits-with-glp1s · general ^[12] New Survey Shows Rise in GLP-1 Drug Coverage for Weight Loss — https://www.mahoneygroup.com/drug-coverage-weight-loss/ · general ^[13] What Insurance Plans Cover Weight Loss Medication in 2026? — https://aaopm.com/blog/insurance-cover-weight-loss-medication/ · general ^[14] GLP-1 Weight Loss Drugs Employer Health Plans: Cost Guide — https://www.washingtonhealthinsuranceagency.com/glp-1-weight-loss-drugs-employer-health-plans-washington-cost-guide · general ^[15] Novo Nordisk’s GLP-1 list price cut. What to watch next — https://www.mercer.com/en-us/insights/us-health-news/novo-nordisks-glp-1-list-price-cut-what-to-watch-next/ · general ^[16] How do prices of drugs for weight loss in the U.S. compare to peer nations’ prices? - Peterson-KFF Health System Tracker — https://www.healthsystemtracker.org/brief/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations/ · general ^[17] GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds — https://www.cbsnews.com/news/glp1-drugs-worker-sick-leave-study/ · professional ^[18] What the Wegovy price cut means for employer sponsored health insurance — https://employercoverage.substack.com/p/what-the-wegovy-price-cut-means-for · general ^[19] Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss — https://www.biospace.com/drug-delivery/novo-slashes-glp-1-prices-again-touts-new-weight-loss-data-on-heels-of-lilly-loss · general ^[20] Wegovy vs Zepbound: Real-World Clinical Data — https://pharmacyknowhow.com/blog/wegovy-vs-zepbound-efficacy/ · general ^[21] How to Budget for Tirzepatide Zepbound Cost in 2026 — https://www.incarenow.com/how-to-budget-for-tirzepatide-zepbound-cost-in-2026/ · general ^[22] Zepbound Cost Without Insurance — https://www.doctronic.ai/blog/zepbound-cost-without-insurance/ · general ^[23] GLP-1 Weight Loss Drugs: An Employer's Guide to Cost & Care — https://carrumhealth.com/blog/glp1-medications-employer-cost-coverage-care/ · general ^[24] How GLP-1 Drugs Are Shaping Care, Cost, and Coverage  - Actuary.org — https://actuary.org/article/how-glp-1-drugs-are-shaping-care-cost-and-coverage/ · general ^[25] GLP-1 Prior Authorization: How It Works — https://devoteddoc.com/glp-1-prior-authorization/ · general ^[26] Evaluating the True Cost of GLP-1 Coverage — https://blog.nisbenefits.com/true-cost-glp-1-coverage · general

Source quality: 1 professional, 25 general.